Morocco is accelerating its emergence as a regional pharmaceutical hub through targeted investments, public–private partnerships, and regulatory reform. Recent developments point to a strategy focused on self-sufficiency, innovation, and export readiness.

In May 2025, Cooper Pharma signed a strategic cooperation agreement with China’s Jemincare Pharmaceutical Group to co-develop advanced therapeutics in Morocco. The deal strengthens Morocco’s ambitions to grow local R&D capabilities and reduce reliance on imports.

Hikma Pharmaceuticals is preparing to launch a new sterile injectable facility in Casablanca by the end of 2025. This move marks a new phase in Hikma’s Moroccan operations and positions the country to supply high-demand, hospital-grade treatments across the region.

Akdital, Morocco’s largest private healthcare operator, is scaling up fast, with plans to expand from 22 to 54 facilities by 2026. While primarily focused on healthcare delivery, Akdital’s expansion strengthens the broader life sciences ecosystem by increasing clinical demand for pharmaceuticals and diagnostics.

Local Market Strength & Regulatory Momentum

• Local manufacturers already meet around 65% of Morocco’s domestic pharmaceutical needs
• Roughly 10% of production is exported across Africa and the MENA region
• Morocco is aligning its regulatory framework with WHO and EU standards, improving GMP certification and clinical trial readiness
• Local firms like LAPROPHAN are innovating with patented treatments and building Morocco’s reputation as a source of quality, export-ready medicines

A Connected Industrial Strategy

These advances are supported by Morocco’s wider industrial policy, which includes:

• The creation of green industrial zones with energy-efficient, circular infrastructure
• Public investment incentives for clean manufacturing, digitalisation, and ESG-aligned production
• The upcoming World Pharma Manufacturing (WPM) showcase at WAM Morocco, connecting global manufacturers, investors and policy leaders to Morocco’s clean pharma infrastructure.

Why It Matters

Morocco’s pharmaceutical sector is evolving quickly in ways that meet international standards and sustainability goals.

Cooper Pharma’s global R&D tie-up, Hikma’s high-tech manufacturing investment and Akdital’s clinical footprint are clear signals of this progress. Combined with green infrastructure and regulatory upgrades, Morocco is laying the groundwork for long-term resilience and competitiveness.

Explore the opportunities at WAM Morocco, the global meeting point for pharma manufacturers and investors focused on clean, scalable industrial growth. Know more and book your space at www.wammorocco.com